Marisa Wexler, MS, senior science writer —

As part of its Path to a Cure initiative, the Cystic Fibrosis Foundation is readying its first “Golden Ticket” Competition, which aims to support early research toward new treatments for cystic fibrosis (CF). The competition will open on May 2, and applications are being accepted through May 30. It…

The first participant has been enrolled in a Phase 1 clinical trial testing the safety and pharmacological properties of the antibiotic Xenleta (lefamulin) in adults with cystic fibrosis (CF). “We are excited to commence enrollment in this important study to evaluate the potential of Xenleta in the management…

The complex diagnostic journey of a girl with cystic fibrosis (CF) and three different disease-causing mutations was described in a report by scientists in Italy. “This case well illustrates possible pitfalls in the clinical and molecular diagnosis of CF,” the researchers wrote. Their report, “Things come…

KIT2014, an experimental treatment that Kither Biotech is developing to treat cystic fibrosis (CF) and other lung diseases, was able to reduce inflammation, relax the airways, and improve the functionality of CFTR modulators in preclinical models, a study shows. Kither is planning to launch a Phase 1/2a clinical…

Antibiotics are less effective at treating lung infections in cystic fibrosis (CF) when there are multiple types of infectious microorganisms present, according to a new study. “People with chronic infections often have co-infection with several pathogens, but the problem is we don’t take that into account in deciding how…

Co-infection with the bacterium Pseudomonas aeruginosa can increase the potency of therapies that kill Candida albicans, an infectious fungus, according to a new study. The study, “Pseudomonas Synergizes with Fluconazole against Candida during Treatment of Polymicrobial Infection,” was published in Infection and Immunity. Pseduomonas and Candida are both microorganisms…

People with mild-to-moderate cystic fibrosis (CF) commonly experience a decline in lung function and an uptick in exacerbations shortly after becoming parents, a study reports. The use of CFTR modulator therapy can lessen the negative health impacts of newfound parenthood, findings also suggest. Its authors called for more research…

The Cystic Fibrosis Foundation has invested $1 million in Felix Biotechnology to support the company’s efforts to develop a phage-based therapy as an alternative to antibiotics in controlling Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). “We are incredibly honored and excited to receive this support from the CF…

For people with cystic fibrosis (CF) who are not eligible for treatment with a CFTR modulator, seeing other patients benefit from these new therapies is “both uplifting and disheartening,” according to a new study. “Although most are happy for those who are benefiting from modulators, they are eager…

Yale University last month launched the Center for Phage Biology and Therapy, a new endeavor to advance research into using viruses to address the growing concern about antibiotic-resistant bacteria. Since the first antibiotics were discovered nearly a century ago, bacteria-killing medicines have revolutionized humanity’s ability to combat bacterial infections. However,…